New Molecular Bridge between RelA/p65 and NF-κB Target Genes via Histone Acetyltransferase TIP60 Cofactor*1

Jung-Woong Kim, Sang-Min Jang, Chul-Hong Kim, Joo-Hee An, Eun-Jin Kang, and Kyung-Hee Choi

From the School of Biological Sciences, Chung-Ang University, Seoul 156-756, South Korea

Received for publication, July 1, 2011, and in revised form, January 13, 2012. Published, JBC Papers in Press, January 16, 2012, DOI 10.1074/jbc.M111.278465

Background: TIP60 is involved in transcriptional regulation acting as a coactivator or corepressor. Also, TIP60 acetylates histones to modulate chromatin remodeling.

Results: TIP60 enhances transcriptional activity of RelA/p65, which is the active subunit of NF-κB through their physical interaction.

Conclusion: TIP60 is critical cofactor of RelA/p65 for transcription of NF-κB target genes.

Significance: TIP60 is involved in the NF-κB pathway in hepatocarcinoma cells.

The nuclear factor-κB (NF-κB) family is involved in the expressions of numerous genes, in development, apoptosis, inflammatory responses, and oncogenesis. In this study we identified four NF-κB target genes that are modulated by TIP60. We also found that TIP60 interacts with the NF-κB RelA/p65 subunit and increases its transcriptional activity through protein-protein interaction. Although TIP60 binds with RelA/p65 using its histone acetyltransferase domain, TIP60 does not directly acetylate RelA/p65. However, TIP60 maintained acetylated Lys-310 RelA/p65 levels in the TNF-α-dependent NF-κB signaling pathway. In chromatin immunoprecipitation assay, TIP60 was primarily recruited to the IL-6, IL-8, C-IAPl, and XIAP promoters in TNF-α stimulation followed by acetylation of histones H3 and H4. Chromatin remodeling by TIP60 involved the sequential recruitment of acetyl-Lys-310 RelA/p65 to its target gene promoters. Furthermore, we showed that up-regulated TIP60 expression was correlated with acetyl-Lys-310 RelA/p65 expressions in hepatocarcinoma tissues. Taken together these results suggest that TIP60 is involved in the NF-κB pathway through protein interaction with RelA/p65 and that it modulates the transcriptional activity of RelA/p65 in NF-κB-dependent gene expression.

The inducible transcription factor (TF) family nuclear factor κB (NF-κB) consists of dimeric complex proteins involved in diverse processes such as controlling cell proliferation, apoptosis, differentiation, and inflammation (1–3). In mammals, there exist five family members, RelA/p65, c-Rel, RelB, p105/p50 (NF-κB1), and p100/p52 (NF-κB2), that homo- or heterodimerize to form transcriptionally active or repressive complexes (4, 5). NF-κB is expressed ubiquitously, and the primary NF-κB member responsible for transcriptional activation of target genes is the subunit RelA/p65 (6). In unstimulated cells, most NF-κB complexes are sequestered in their inactive forms by interactions with inhibitors of κB (IκB) proteins in the cytoplasm (3, 7). After stimulation, IκB is phosphorylated by the IκB kinase (IKK) complex and rapidly undergoes ubiquitination and proteasome-dependent degradation (8–10). The NF-κB subunits are then released and accumulate in the nucleus to regulate target gene transcription (11, 12).

After nuclear translocation, NF-κB complexes utilize various strategies to achieve proper TF binding when recognition sites are buried in chromatin. Previous researchers proposed that TFs can bind to nucleosomal DNA in a cooperative manner (13, 14). This has been confirmed by in vivo studies showing that transcriptional activator Pho4 can bind to the PHO5 promoter before nucleosome disassembly (15). In other cases, chromatin remodeling complexes can further stimulate binding of TFs to the nucleosomal sites (16). In a large scale screening of the human genome, high levels of histone H3K4me7 methylation and H3 acetylation were found to be prerequisites for binding of the transcription factor Myc, which implies that chromatin modifications can actually regulate TF binding (17).

Transcriptional activation of NF-κB involves the association of NF-κB with various cofactors including histone acetyltransferase (HAT) p300/CBP and the nuclear receptor coactivators SRC3/Rac3 and SRC1/N-CoA1 (18–21). These cofactors are thought to promote the rapid formation of preinitiation and reinitiation complexes by bridging sequence-specific activators to the basal transcription machinery, thereby facilitating multiple rounds of transcription (20, 21). Enhancement of NF-κB transcriptional activity requires the factor acetyltransferase activity of p300/CBP and P300/CBP-associated factor (PCAF). How these various coactivators are recruited to the promoter regions of NF-κB target genes and when they associate with NF-κB transcription factors are not very clear.

TIP60 (HIV Tat-interacting protein, 60 kDa) was identified as a binding partner for the HIV-1 Tat protein, which increases Tat transactivation of the HIV-1 promoter (25). The MYST (MOZ, Ybf2/Sas3, Sas2, and TIP60) domain defines TIP60 as
part of the MYST family of HAT proteins that are conserved from yeast to human (26). TIP60 functions as a transcriptional coactivator or corepressor depending upon the cellular context or promoter site (27). As a coactivator, TIP60 associates with transcriptional activators such as HIV-1 Tat (25), amylod-β precursor protein (28), type I nuclear hormone receptors (29, 30), and MyoD (31). The coactivator function in these instances is mediated by histone acetylation within the promoter region, whereas in other cases TIP60 directly acetylates p53 transcription factor and thus modulates transcriptional activity. It helps to distinguish between the cell cycle arrest and apoptotic functions of p53 (32, 33). In contrast, TIP60 has also been implicated in the negative regulation of gene expression by binding to STAT3 (34), CREB (cAMP response element-binding protein) (35), ZEB (zinc finger E box-binding protein) (36), and p73 (37). Although a growing number of TFs have been identified as transcriptional regulatory targets of TIP60, the precise mechanisms by which TFs are involved in TIP60-mediated transcriptional regulation and contribute to the various cellular physiological modifications remain to be elucidated.

In this study we identified four NF-κB target genes, IL-6, IL-8, C-IAP1, and XIAP, whose expressions are regulated by TIP60. Furthermore, we found that TIP60 is a novel coactivator of NF-κB RelA/p65 and enhances RelA/p65 transcriptional activity through a protein-protein interaction. We also present the sequential association profiles of TIP60 and RelA/p65 on the NF-κB target gene promoters with the goal of determining the critical association time point in the TNF-α-induced NF-κB signaling pathway. Although it is generally accepted that TFs primarily bind to specific promoters and trigger a recruitment cascade of coactivator complexes, interestingly, we found that TIP60 appeared and bound earlier to the NF-κB target promoters than RelA/65, and it simultaneously promoted the acetylation of histones. Thus, site-specific early association of TIP60 could serve as the platform for transcription factor RelA/p65 binding sites to promote NF-κB-mediated gene expression.

**EXPERIMENTAL PROCEDURES**

**Cell Culture and Transfection**—HEK 293 and HepG2 cells were obtained from ATCC (American Type Culture Collection) (Manassas, VA). RelA/p65 knock-out mouse embryonal fibroblast (RelA/p65−/− mouse embryonal fibroblast (MEF)) cells were kindly gifted from Professor Jin Won Cho in Yonsei University (Korea), and RelA/p65 wild type MEF (RelA/p65+/+) MEF cells were provided from Professor Sangmyung Rhee in Chung-Ang University (Korea). Cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (Invitrogen) and penicillin-streptomycin (50 units/ml). Transient transfection was conducted using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

**Plasmid Construction**—The human TIP60 full-length coding region was amplified from hTIP60 cDNA in the human brain library (Clontech) using polymerase chain reaction (PCR) and was introduced to pCRII-TOPO vector (Invitrogen), which was called pCRII-TOPO-TIP60. The TIP60 clone was verified by DNA sequencing. TIP60 full-length was amplified from pCRII-TOPO-TIP60 using a PCR reaction: forward 5′-gaa ttc ATG GCG GAG GTG-3′; reverse 5′-tct aga TCA CCA CTT CCC CCT TTG-3′. TIP60-chromo, TIP60-Zn, and TIP60-HAT truncated mutants were amplified from TIP60-full-length using a PCR reaction: for TIP60-chromo, forward 5′-gaa ttc ATG GCG GAG GTG GTG-3′ and reverse 5′-tct aga GAG GAC AGG CAA TTG TGT-3′; for TIP60-Zn, forward 5′-gaa ttc ACC CCC ACT AAG AAC AC-3′ and reverse 5′-tct aag ATT GTA GTC TTG CGT-3′; for TIP60-HAT, forward 5′-gaa ttc CTA CGA CAT CCT CCA-3′ and reverse 5′-tct aga TCA CCA CTT CCC CCT TTG-3′. These PCR products were introduced into the pCI-TOPO vector (Invitrogen) and subcloned into the pEGFPC2 vector between EcoRI and XbaI and then verified by DNA sequencing. Oligonucleotide for TIP60 siRNA was introduced into the pBabe-dual vector: forward 5′-aag CCG AAC GTG GAG GTG-3′, reverse 5′-aaa CAC CTC CAC CTT CCG TTT TTT-3′. FLAG-TIP60 HAT-deficient mutant expression vector was a gift from S. H. Baek in the School of Biological Science at Seoul National University. RelA/p65 full-length cDNA was subcloned into the pFLAG-CMV2 vector (Sigma) and pCDNA3-HA vector. Expression vectors for GST-fused RelA/p65 full-length, RelA/p65 N320, and RelA/p65 C321 were gifts from Professor Cheol O. Joe in KAIST (38).

**RNA Preparation and Quantitative Real-time PCR**—Total RNA was extracted from HEK 293, HepG2, and MEF cell lines using TRIzol solution (Invitrogen) according to the manufacturer’s specifications. Contaminated genomic DNA was removed from 5 μg of total RNA by incubation with 10 units of RNase-free DNase I (New England Biolabs) and 2 units of RNase inhibitor (New England Biolabs) in DEPC-treated water. The reaction mixture was incubated for 1 h at 37 °C and then for 10 min at 60 °C. RNA concentrations were determined by spectrophotometric analysis. All RNA isolates had an absorbance at 260 nm between 1.8 and 2.0, indicating that the isolated RNA was suitable for subsequent analyses. Oligo-dT (Invitrogen), Seoul, Korea) was used as the primer in the first step of cDNA synthesis. Total RNA (1 μg) was combined with 0.5 μg of oligo-dT, 200 μM dNTPs, and H2O and then preheated at 75 °C for 5 min to denature the secondary structures. The mixture was then cooled rapidly to 20 °C, after which 4 μl of 5× reverse-transcriptase buffer, 10 mM DTT, and 200 units of avian myeloblastosis virus reverse transcriptase (Invitrogen, Seoul, Korea) was added to give a total volume of 20 μl. The reverse-transcriptase mix was incubated at 42 °C for 60 min, after which it was stopped by heating at 95 °C for 5 min. The PCR primers used in this study and their sequences are listed in supplementary information 1 and 2. The primers were designed using the Primer 3 program and cross-checked by a BLAST search of the NCBI data base. The specificity of each of the amplified products generated was confirmed by melting curve analysis. The iQ SYBR Green PCR Supermix (Bio-Rad) and the CFX96 Real-time PCR detection system (Bio-Rad) were used to detect the real-time quantitative PCR products of reverse-transcribed cDNA or chromatin immunoprecipitation (ChIP) samples according to the manufacturer’s instructions. The GAPDH gene was used for normalization. The relative mRNA expression was calculated by the 2−ΔΔCT method as previously described (39). PCR was conducted in duplicate for each experimental condition tested.
Luciferase Assay—HEK 293 and HepG2 cells were cultured in 60-mm dishes and transfected using Lipofectamine 2000, with the luciferase reporter constructs (0.1 μg), pCMV-β-galactosidase, RelA/p65, and TIP60 constructs. The cells were lysed in reporter lysis buffer 48 h after transfection (Promega, Madison, WI). Cell extracts were analyzed with the luciferase reporter assay system using a glomax luminometer (Promega). Luciferase activities were normalized based on the β-galactosidase activity of the cotransfected vector. All transfection experiments were repeated independently at least three times.

In Vivo Binding Assay and Western Blotting—HEK 293 and HepG2 cells were seeded in 100-mm plates at an initial density of 2 × 10^6 cells and allowed to grow for 12 h. The cells were transfected with the respective plasmids, further incubated for 24 h, and lysed in a buffer containing 1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 0.1% sodium dodecyl sulfate (SDS), 1% Nonidet P-40, and 1 mM PMSF. The cell suspensions were incubated on ice for 20 min and centrifuged at 12,000 rpm at 4 °C for 20 min. For immunoprecipitation assays, the supernatants were precleared with 20 μl of protein A/G-agarose bead (50% slurry) and then incubated at 4 °C overnight with 40 μl of fresh protein A/G bead in the presence of appropriate antibodies. The beads were washed 3 times in PBS, resuspended in SDS sample buffer, and boiled for 10 min. The protein samples were electrophoresed on a 10% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane (Whatman, PROTRAN). The membrane was blocked with 5% skim milk in a solution of 20 mM Tris-HCl, pH 7.6, 137 mM NaCl, and 0.1% Tween 20 and incubated with appropriate dilutions of the primary antibody at room temperature for 3 h. Samples were analyzed by Western blotting using the appropriate antibodies to detect protein expression. Polyclonal antibodies against TIP60 (sc-5725), RelA/p65 (sc-109), HA-probe (sc-805), and β-tubulin (sc-397) were purchased from Santa Cruz Biotechnology Inc., and Ac-Lys-310 Rel/p65 was purchased from Abcam. Monoclonal antibodies against green fluorescence protein (GFP-1814 460), FLAG-M2 (F3165), and Ac-lysine (sc-32268) antibodies were purchased from Roche Diagnostics, Sigma, and Santa Cruz Biotechnology, respectively.

ChIP—A ChIP assay was conducted following the protocol provided by Millipore (Temecula, CA). Briefly, the cultured cells were cross-linked with 1% paraformaldehyde (#15710, Electron Microscopy Sciences, Hatfield, PA) in PBS for 15 min at 37 °C. The cells were then washed with ice-cold PBS and resuspended in 200 μl of SDS-sample buffer containing a protease inhibitor mixture. The suspension was sonicated 3 times for 10 s with a 1-min cooling period on ice, after which it was precleared with 20 μl of protein A/G-agarose beads blocked with sonicated salmon sperm DNA for 30 min at 4 °C. The beads were then removed, after which the chromatin solution of each experimental group was immunoprecipitated overnight with anti-TIP60 (sc-5725, Santa Cruz Biotechnology), RelA/p65 (sc-109), Ac-Lys-310 RelA/p65 (ab19870, Abcam, Cambridge, MA), Ac-K18 histone H3 (1766–1, Epitomics, Burlingame, CA), Ac-K8 histone H4 (1796–1, Epitomics), and polymerase II (2035–1, Epitomics) antibodies at 4 °C followed by incubation with 50 μl of protein A-agarose beads (Millipore) for an additional hour at 4 °C. The immune complexes were eluted with 100 μl of elution buffer (1% SDS and 0.1 M NaHCO3), and formaldehyde cross-links were reversed by heating at 65 °C for 4 h. Proteinase K (P2308, Sigma) was added to the reaction mixtures and incubated at 45 °C for 1 h. DNA of the immunoprecipitates and control input DNA were purified using the PCR purification kit (Qiagen, Valencia, CA) and then analyzed by quantitative PCR. The PCR primers used in ChIP assay and their sequences are listed in supplemental data. PCR was conducted in duplicate for each experimental condition tested.

Immunofluorescence Staining and Confocal Microscopic Detection—HepG2 cells were grown on a sterile coverslip in 60-mm dishes and transfected with indicated expression vectors using Lipofectamine 2000. Twenty-four hours after transfection, cells were fixed with 4% paraformaldehyde and incubated with mouse anti-FLAG M2 antibody (1:1000) (Sigma) followed by Cy5-conjugated goat anti-mouse (ab97035, Abcam). Plates were washed three times in PBS, and confocal imaging was performed with a Carl Zeiss LSM-510 META laser scanning microscope (Oberkochen, Germany).

Immunohistochemistry and Tissue Array—Formalin-fixed paraffin-embedded tissue microarray slides containing hepatocarcinoma and normal liver tissues were purchased from Super Biochips (Seoul, Korea). Briefly, after deparaffinization in xylene and rehydration in grade ethanol, endogenous peroxidase activity was blocked by incubation with 3% hydrogen peroxide for 10 min. Tissue sections were then heated in 100 mM citrate buffer, pH 6.0, for 10 min to retrieve antigens and preincubated with normal horse serum for 20 min at room temperature. Anti-TIP60 (sc-5725) and Ac-Lys-310 RelA/p65 antibodies (ab19870) diluted 1:100 was used as the primary antibody, and the specimens were incubated with appropriate antibodies overnight at 4 °C followed by the addition of biotinylated anti-goat and rabbit secondary antibody ( Vectastain Laboratory) and streptavidin-horseradish peroxidase (Zymed Laboratories Inc., South San Francisco, CA). 3,3-Diaminobenzidine was used as a chromogen, and Meyer’s hematoxylin was used for counterstaining. For negative control purposes, the same procedure was followed except that the primary antibody was replaced by PBS. The level of TIP60 and Ac-Lys-310 RelA/p65 expressions was calculated by the staining intensity using Quantity One software (Bio-Rad). Staining intensity was rated on a scale of 0–3 as follows: 0, negative (no color); 1, weak (weak yellow); 2, moderate (yellow); 3, strong (brown). The intensity score ≥2 was considered as positive expression.

Cell Proliferation Assay—For the assay of colony-forming efficiency in soft agar, transfected HepG2 cells were counted using a hemocytometer. 5 × 10^3 cells in 1 ml of growth medium containing 0.35% Noble agar (Difco) and G418 (800 μg/ml) were incubated in a 60-mm culture dish overlaid on 1.5 ml of 0.5% base agar medium. Cells were incubated at 37 °C in a moist atmosphere of 95% air and 5% CO2, and 4 weeks later the number of colonies was counted after 0.005% crystal violet staining.

Statistical Analysis—Statistical analysis of variances between two different experimental groups was conducted with Tukey’s post hoc comparison test using SPSS (Version K12). All experiments were repeated at least three times. The levels were considered significant at p < 0.05 (shown as a single asterisk), very
significant at $p < 0.01$ (shown as double asterisks), obviously significant at $p < 0.001$ (shown as triple asterisks), or not significant (n.s.).

**RESULTS**

**TIP60 Regulates the Expression of NF-κB Target Genes**—TIP60 functions critical roles in development, damage responses, and apoptosis, acting as “Herb genes” (27, 40). However, the genes regulated by TIP60 are not well identified. To screen the TIP60-regulated genes, HEK 293 cells were transfected with FLAG-TIP60 plasmid, and mRNA expression was analyzed by semiquantitative RT-PCR. As shown in the supplemental information 3a, IL-6, IL-8c caspase-7, Bad, Bax, Bcl-2, C-IAP1, and XIAP mRNA expressions were increased by TIP60. However, IL-5, p38, ERK-2, ERK-3, ERK-5, caspase-2, and caspase-10 expressions were down-regulated by TIP60 overexpression. Because TIP60 modulates transcriptional activity of transcription factors as a coactivator and corepressor, we tried to identify co-regulatory transcriptional factors of TIP60 that might bind to TIP60-responsive gene promoters, such as IL-6, IL-8, caspase-7, Bad, Bax, Bcl-2, C-IAP1, and XIAP, using TFSEARCH software (Searching Transcription Binding Sites Version 1.3). Several transcription factors overlapped as putative binding factors for these promoter regions including RelA/ p65, p53, and AP-1. Interestingly, we found that the RelA/p65 binding site was the most frequent and highly conserved motif among the IL-6, IL-8, XIAP, and C-IAP promoters (supplemental information 3b). To examine whether TIP60 regulates RelA/ p65-mediated transcriptional activity, HEK 293 cells were transfected with FLAG-TIP60 plasmids together with an NF-κB-responsive element luciferase reporter gene with treatment with known activators of NF-κB such as TNF-α, lipopolysaccharide (LPS), and IL-1β. TNF-α, LPS, and IL-1β treatment increases transcriptional activity of the NF-κB reporter gene by activating endogenous RelA/p65 (Fig. 1a, lanes 2, 6, and 10), and TIP60 most significantly enhances transcriptional activity on NF-κB reporter gene in a dose-dependent manner within TNF-α-treated groups than other signaling molecules (Fig. 1a, lanes 3 and 4). To confirm TIP60-mediated transcriptional enhancement on NF-κB target genes, HEK 293 cells were transfected with the FLAG-TIP60 plasmid, and the mRNA expression was analyzed by semiquantitative RT-PCR. Overexpression of TIP60 enhances mRNA expression of IL-6, IL-8, C-IAP1, and XIAP in TNF-α-treated cells (Fig. 1b, lane 3). To further examine whether the increased expression of IL-6, IL-8, C-IAP1, and XIAP transcripts was specifically modulated by TIP60 through RelA/p65 pathway, we used TIP60 small interfering RNA (siRNA) transfectants of RelA/p65 +/+ MEF or p65 −/− MEF cells in which the expression of TIP60 was ~80% abrogated (supplemental information 3c). As shown in Fig. 1c, transfection of TIP60 siRNA significantly decreased the endogenous RelA/p65-mediated transcription of IL-6, IL-8, C-IAP1, and XIAP in TNF-α-treated MEF cells. Taken together, TIP60 increases transcriptional activity of NF-κB RelA/p65 and enhances the expression of RelA/p65 responsive genes, IL-6, IL-8, C-IAP1, and XIAP.

**TIP60 Interacts and Co-localizes with RelA/p65**—To examine whether TIP60 could affect RelA/p65-dependent transcriptional activity through protein-protein interactions, we exogenously expressed HA-RelA/p65 along with FLAG-TIP60 with TNF-α treatment in HEK 293 cells. The whole cell lysates were co-immunoprecipitated with anti-FLAG antibodies, and we performed Western blotting using specific anti-HA and FLAG antibodies to determine RelA/p65 and TIP60 expression levels. FLAG-TIP60 co-immunoprecipitated with HA-RelA/p65 (Fig. 2a, lane 2) but did not coprecipitate with control FLAG-empty vector (Fig. 2a, lane 1). Conversely, exogenous HA-RelA/p65 also co-immunoprecipitated with FLAG-TIP60 (Fig. 2b, lane 2) but not with the control HA empty vector (Fig. 2b, lane 1). These results suggest that TIP60 physically interacts with RelA/ p65 in HEK 293 cells. To further investigate whether RelA/p65 interacts with TIP60 endogenously in vivo, HepG2 cells were treated with 50 ng/ml TNF-α for 60 min; untreated cells served as negative controls. Whole cell lysates were immunoprecipitated with anti-TIP60 antibodies together with their control rabbit sera, and Western blotting was performed using anti-RelA/p65 or anti-TIP60 antibodies. We clearly observed that...
TIP60 endogenously interacts with RelA/p65 in TNF-α-treated HepG2 cells (Fig. 2c, lane 4). These results demonstrate that the physical interaction between TIP60 and RelA/p65 was increased in TNF-α-treated HepG2 cells in vivo.

To determine the subcellular localization of the TIP60-RelA/p65 complex in the nucleus, HepG2 cells were co-transfected with GFP-TIP60 and FLAG-RelA/p65 expression plasmids, and the cells were immunostained using anti-FLAG antibodies (Fig. 2d). Inactivated RelA/p65 (magenta) mostly sequestered in the cytoplasm (~60%), whereas TIP60 (green) intrinsically located in the nucleus (~90%). TNF-α treatment resulted in RelA/p65 accumulation into TIP60 condensed sites (~70%), which mostly co-localized with chromatin (supplemental information 4a). To further elucidate the distribution patterns within these formations, we subjected our confocal image stack to z axis analysis (supplemental information 4b), which revealed an apparent overlap of localization in the nucleus between TIP60 and RelA/p65 upon TNF-α treatment.

TIP60 HAT Domain Interacts with RelA/p65 N-terminal Rel Homolog Domain Region—To define the region of TIP60 that is required for interactions with RelA/p65, HepG2 cells were transfected with TIP60 encoding GFP fused to full-length TIP60, the TIP60 chromo domain (TIP60-Ch), the TIP60 zinc finger domain (TIP60-Zn), or the TIP60 histone acetyltransferase domain (TIP60-HAT) together with the FLAG-RelA/p65 expression plasmid (Fig. 3a, upper panel). After whole cell lysates were immunoprecipitated with anti-FLAG antibodies, Western blotting was performed with anti-FLAG and anti-GFP antibodies. Although chromo (amino acids 1–260) and zinc finger (amino acids 27–366) domain-containing regions of TIP60 did not appear to interact with FLAG-RelA/p65, the HAT domain-containing region (amino acids 285–513) strongly interacted with FLAG-RelA/p65 (Fig. 3a, lower panel), showing that RelA/p65 interacts with histone acetyltransferase domain of TIP60.

To determine the binding region of RelA/p65 necessary for interaction with TIP60, HepG2 cells were transfected with the RelA/p65 encoding GST fused to the RelA/p65 full-length, N-terminal 320 amino acid-containing region (N320) and the C-terminal transactivation domain containing region (C321) together with FLAG-TIP60 expression plasmid (Fig. 3b, upper panel). Whole cell lysates were immunoprecipitated with anti-GST antibodies, and then Western blotting was performed with anti-FLAG and anti-GST antibodies. As shown in the lower panel of Fig. 3b, TIP60 strongly interacts with the N-terminal Rel homology region (RHR) (amino acids 1–320) of RelA/p65 but not with the C-terminal region (amino acids 321–511). All together, these results demonstrate that the HAT domain of TIP60 interacts with the N-terminal Rel homology-containing region of RelA/p65 in HepG2 cells.

TIP60 Increases Transcriptional Activity of RelA/p65 through Physical Interactions—To demonstrate whether TIP60 could affect RelA/p65-dependent transcriptional activation through a protein–protein interaction, HepG2 cells were co-transfected with TIP60-truncated mutants (described in Fig. 3a, upper panel) together with the FLAG-RelA/p65 expression plasmid plus a luciferase reporter gene-containing NF-κB response element. The transcriptional activity of RelA/p65 was significantly enhanced by the full-length TIP60 and the HAT domain-containing region of TIP60 (Fig. 4a, third and sixth lanes) but not by the chromo and the zinc finger domains of TIP60 (fourth and fifth lanes), indicating that a physical association with the HAT domain of TIP60 is necessary for enhancement of RelA/p65 transactivation. To further examine whether the enhanced
transcriptional activity of RelA/p65 was specifically modulated by TIP60, we used siTIP60 transfectants of RelA/p65/H11001/H11001 MEF or p65/H11002/H11002 MEF cells. As shown in Fig. 4b, transfection of TIP60 siRNA significantly decreased the endogenous RelA/p65-mediated transcriptional activation on NF-κB promoter (sixth and eighth lanes). Indeed, a knockdown of TIP60 also specifically eliminated TIP60-mediated enhancement of transcriptional activity of overexpressed RelA/p65 (Fig. 4c, fourth lane). Because RelA/p65 interacted with the HAT domain of TIP60 and their interaction was required for full transcriptional activation of RelA/p65, we used TIP60 HAT mutant to demonstrate whether TIP60 enhances the transcriptional activity of RelA/p65 through its HAT activity. HepG2 cells were co-transfected with HA-RelA/p65 together with the FLAG-TIP60 wild type or HAT mutant expression plasmid plus a luciferase reporter gene containing NF-κB-response element. As shown in Fig. 4d, TIP60 enhanced the transcriptional activity of RelA/p65 in a dose-dependent manner (third and fourth lanes). However, TIP60 HAT mutant lacks the ability of transcriptional activation of RelA/p65, although it increases expression of TIP60 HAT mutant (fifth and sixth lanes). Taken together, our results show that TIP60 HAT activity is required for RelA/p65-mediated transcriptional activation through a physical interaction.

TIP60 Is Recruited to Subset of NF-κB Target Gene Promoters and Is Required for Full Transcriptional Activation of RelA/p65—Having identified TIP60 as a coactivator of RelA/p65 through a physical interaction, we next conducted a ChIP assay to examine whether TIP60 is recruited to the promoter of NF-κB target genes in vivo, an essential step for the function of a coactivator. ChIP patterns were obtained from chromatin prepared from HepG2 cells treated with 50 ng/ml TNF-α; correlations were found between TIP60 and RelA/p65 on target gene promoters (supplemental information 5a). To further dissect the sequential protein association to NF-κB target promoters, each promoter was examined by quantitative PCR of ChIP samples using the indicated appropriate primers (Fig. 5). Also, IgG and water negative controls for antibodies were presented in supplemental information 5b. We stimulated HepG2 cells with TNF-α for 0, 15, 30, 45, and 60 min and examined the binding of TIP60, acetylated histones, RelA/p65, acetylated lysine 310 RelA/p65, and RNAP II to the promoters of IL-6, C-IAP, IL-8, and XIAP, the expression of which is regulated by TIP60. In the absence of TNF-α stimulation, the binding of TIP60, RelA/p65, Ac-Lys-310 RelA/p65, and RNAP II to the each promoter was barely detected (time point 0 min at each experimental groups). After TNF-α stimulation (during 0–30 min), RelA/p65, Ac-Lys-310 RelA/p65, acetylated histones, and RNAP II were recruited to the promoters of IL-6, C-IAP, IL-8, and XIAP, the expression of which is regulated by TIP60. In the absence of TNF-α stimulation, the binding of TIP60, RelA/p65, Ac-Lys-310 RelA/p65, and RNAP II to the each promoter was barely detected (time point 0 min at each experimental groups). After TNF-α stimulation (during 0–30 min), RelA/p65, Ac-Lys-310 RelA/p65, acetylated histones, and RNAP II were recruited to the promoters of IL-6, C-IAP, IL-8, and XIAP, the expression of which is regulated by TIP60. Importantly, TIP60 was first recruited to each promoter during TNF-α treatment until 15 min (Fig. 5; a1–a4), and then histone acetylation occurred on NF-κB target gene promoters (Fig. 5, b and c). Accompanied by TIP60 association, total RelA/p65 and Ac-Lys-310 RelA/p65 were cooperatively recruited to IL-6, C-IAP, IL-8, and XIAP promoters (Fig. 5, d and e). However, when we transfected HepG2 cells with TIP60 siRNA, recruitment of RelA/p65, Ac-Lys-310 RelA/p65, TIP60, and RNAP II was significantly reduced, demonstrating the specificity of the recruitment by TIP60 association. These quantitative ChIP data suggest that TIP60 is recruited to the
TIP60 Enhances Transcriptional Activity of RelA/p65

**FIGURE 4. Enhancement of the transcriptional activity of RelA/p65 by the protein interaction with TIP60.** a, HepG2 cells were co-transfected with combined expression plasmids of FLAG-RelA/p65 and GFP-fused full-length (FL), chromo (Ch), zinc finger, and HAT domains of TIP60 together with a luciferase reporter plasmid containing the NF-κB promoter. Luciferase activities (Luc) were measured 24 h after the transfection as described under "Experimental Procedures." b, RelA/p65wt or RelA/p65HAT was transfected with pBabe-TIP60 siRNA plasmid or its control empty vector and treated with 50 ng/ml TNF-α for 1 h to activate NF-κB pathway. Luciferase activities were measured 24 h after the transfection. c, HepG2 cells were co-transfected with expression vector FLAG-RelA/p65, GFP-TIP60, siRNA for TIP60, and luciferase reporter plasmid (0.1 μg). Luciferase activities were measured 24 h after the transfection. d, HepG2 cells were transfected with HA-RelA/p65 and FLAG-TIP60 or FLAG-TIP60 HAT mutant-expressing plasmids together with luciferase reporter plasmid. Luciferase activities were measured 24 h after transfection. The data were normalized to β-galactosidase activity and are expressed in relative-fold increase of luciferase units. All data are representative of three independent experiments, and statistical significance is represented by Tukey’s post hoc test (**, p < 0.01; ***, p < 0.001; n.s., not significant).

promoters of a subset of NF-κB target genes, and TIP60 association is critical step for subsequent recruiting events on target gene promoters during the activation of the NF-κB pathway.

**TIP60 Maintains Ac-Lys-310 RelA/p65 Levels through Their Protein Interaction**—In previous reports it was shown that TIP60 enhances transcriptional activity of the transcription factor p53 through the acetylation of the Lys-121 residue (32, 33). Therefore, we hypothesized that TIP60 may increase the transcriptional activity of RelA/p65 through direct acetylation of RelA/p65 by a physical interaction with the TIP60-HAT domain. To test this hypothesis, we first investigated the acetylation levels of RelA/p65 affected by TIP60 overexpression. HepG2 cells were transiently transfected with either an empty FLAG vector and FLAG-TIP60 wild type or FLAG-TIP60 HAT mutant together with the HA-RelA/p65 expression plasmid. The transfected cells were treated with trichostatin A to inhibit deacetylation of RelA/p65 by histone deacetylase. After the whole cell lysates were immunoprecipitated with anti-HA antibody, Western blotting was performed with anti-acetylated lysine, anti-Ac-Lys-310 RelA/p65, anti-HA, and anti-FLAG antibodies. Total acetylated RelA/p65 levels were clearly increased in the presence of TIP60 expression (Fig. 6a, lane 2), in contrast to the control group (lane 1). However, although TIP60 HAT mutant effectively associated with RelA/p65, both total acetylated RelA/p65 and Ac-Lys-310 RelA/p65 were not reduced by TIP60 HAT mutant overexpression (lane 3). To further verify the acetylation of RelA/p65 by TIP60, we performed an in vitro acetylation assay using affinity-purified TIP60 and RelA/p65. Consistent with overexpression data in Fig. 6a, we did not observe the acetylated RelA/p65 by TIP60, although TIP60 did acetylate itself (supplemental information 6), TIP60 autoacetylation was previously reported; Ref. 41).

Because TIP60 increased the levels of Ac-RelA/p65 without direct RelA/p65 acetylation in vitro and in vivo, we next examined the TNF-α-induced endogenous Ac-RelA/p65 protein levels in the absence or presence of TIP60. HepG2 cells were transfected with or without the FLAG-TIP60 plasmid together with HA-RelA/p65, and the cells were treated with TNF-α for the indicated time points. After the whole cell lysates were immunoprecipitated with anti-HA antibodies, Western blotting was performed with anti-Ac-Lys-310 RelA/p65 and anti-HA antibodies. As shown in Fig. 6b, TIP60 stabilized Ac-Lys-310 RelA/p65 contrast to the TIP60 absent group. These data showed that Ac-Lys-310 RelA/p65 status was increased by the presence of TIP60 from the 30- to 120-min time points after TNF-α treatment. To further confirm the TIP60-mediated stabilization of RelA/p65 in vivo, we used TIP60 siRNA transfectants of HepG2 cells. As shown in Fig. 6c, knockdown of TIP60 using its specific siRNA markedly reduced the Lys-310-acetylated RelA/p65 contrast to control vector-transfected groups. Taken together, our results show that TIP60 stabilizes Ac-Lys-310 RelA/p65 through a physical interaction.

**Increased Expression of Ac-Lys-310 RelA/p65 and TIP60 in Hepatocarcinoma Tissues**—To examine whether TIP60 regulates the hepatocarcinoma cell growth, we examined colony-forming abilities in the HepG2 cells. The cells were transfected with FLAG-TIP60 or TIP60 siRNA and maintained for 4 weeks in G418 containing soft agar medium, and drug-resistant colonies were stained with crystal violet. As shown in Fig. 7a, whereas large numbers of colonies were observed in the empty vector-transfected control group, only a few colonies were observed in the TIP60 siRNA-transfected group (upper right panel). Conversely, TIP60 overexpression induced the increase of colony-forming abilities in HepG2 cells (lower right panel). These data demonstrate that TIP60 regulated the HepG2 liver cancer cell proliferation under physiological conditions.

To identify the expression levels of TIP60, which is involved the enhancement of transcriptional activity of NF-κB in hepatocarcinoma, we performed immunohistochemical analysis for Ac-Lys-310 RelA/p65 and TIP60 on a paraffin-embedded human hepatocarcinoma tissue microarray (Fig. 7b). This tissue microarray contained a total of 59 tissue spots consisting of 38 hepatocarcinoma, 2 cholangiocarcinoma, 10 metastatic hepatocarcinoma, and 9 non-neoplastic liver tissue samples, which are adjacent to cancer tissues. In the normal hepatocytes, the positive rate of TIP60 expression was 22.2% (2/9) (upper,
left panel). However, positive expression of TIP60 was significantly increased ($p < 0.01$) in hepatocarcinoma (34.2%, 13/38) (upper, right panel). We also confirmed the expression level of Ac-Lys-310 RelA/p65 by tissue microarray. As shown in previous reports (42, 43), we detected the up-regulated positive expression of Ac-Lys-310 RelA/p65 in hepatocarcinoma cells (71%, 27/38) (bottom, right panel). Among TIP60 up-regulated tissues (13/38), 11 tissues (84.6%, 11/13) overlapped with Ac-Lys-310 RelA/p65-enhanced groups. TIP60 expressions were significantly up-regulated in TNM (tumor, node, metastasis) stage II hepatocarcinoma, and its histological properties were well or moderately differentiated hepatocytes (Table 1). These tissue microarray data showed that up-regulated TIP60 expression was significantly correlated with Ac-Lys-310 RelA/p65 expressions in hepatocarcinoma tissues.

**DISCUSSION**

Histone acetylation by HATs plays important roles in the regulation of gene expression. HATs are generally thought to activate transcription by loosening compacted chromatin and by opening binding sites for the chromatin proteins or TFs, which facilitate the access of the transcriptional machinery to the DNA (44). There are five families of HATs: Gcn5-related HATs, p300/CBP HATs, general transcription factor HATs, nuclear hormone receptor-related HATs, and the MYST family of HATs. The MYST family is named for its founding members MOZ, Ybf2/Sas3, SAS2, and TIP60 (26). MYST family members function in a broad range of biological processes, such as gene regulation, dosage compensation, repair of DNA damage, and tumorigenesis (26, 45).

Although growing evidence suggests that TIP60 plays an important role in the transcriptional regulation of transcription factors acting as coactivator or corepressor, TIP60-mediated gene expression regulation is not well determined. Because TIP60 is not a transcription factor that recognizes specific DNA sequences, it requires the selective function of transcription factors to regulate the expression of specific target genes. In this regard it is necessary to identify TIP60-regulated transcription factors to elucidate the TIP60-modulated genes. In this study we found that the gene expressions of *IL-6*, *IL-8*, caspase-7, *Bad*, *Bax*, *Bcl-2*, *cIAP*, and *XIAP* are increased by TIP60 overexpression (supplemental information 3a). Among these genes, the in silico method showed that *IL-6*, *IL-8*, *cIAP*, and *XIAP* have conserved NF-κB binding sites in their promoter regions (supplemental information 3b). Previous studies revealed that *IL-6*, *IL-8*, *XIAP*, and *cIAP* were modulated by NF-κB RelA/p65 as target genes (46–50). We demonstrated that TIP60 is involved in NF-κB pathway through activating the transcrip-
tional activity of RelA/p65 in response to TNF-α/H9251 stimulation (Fig. 1a). TIP60-mediated enhancement of transcriptional activation of RelA/p65 was also confirmed by knockdown of TIP60 (Figs. 1c and 4, b and c). Thus, we propose that TIP60 has a coactivator function in the NF-κB signaling pathway like other cofactors, such as p300/CBP, PCAF, and Brd4 (22, 51).

TIP60 involvement in NF-κB transcriptional activation was previously described by Baek et al. (52). In unstimulated cells, the IL-1β/H9252/NF-κB-regulated KAI1/CD82 gene promoter is repressed by a corepressor complex that contains NCoR, histone deacetylase 3, and TAK1-binding protein 2 (TAB2) (52). In response to IL-1β cytokines, the NCoR complex is phosphorylated and exported from the nucleus, thus allowing a TIP60-coactivating complex to bind and derepress the KAI1 promoter.
(52). This TIP60 complex contains TRRAP and is recruited to NF-κB p50 homodimer complexes bound to the promoter via interactions with the NF-κB adaptor protein B-cell lymphoma/lymphoma 3 (Bcl3), which is accompanied by acetylation of histones H3 and H4 in a promoter-specific fashion (52). They provided a possible role of TIP60 in NF-κB-regulated gene expression acting as a coactivator through distinct mechanisms (gene activation with NF-κB p50/p50 homodimer). Our findings indicate that the association of TIP60 with NF-κB RelA/p65 is critical for interaction with TIP60 in this study, it seems that p300-mediated RelA/p65 could not directly acetylate RelA/p65, we found that acetyl-Lys-310 RelA/p65 was maintained by TIP60 overexpression with TNF-α stimulation (Fig. 6b). It is possible that TIP60 interacts with the N-terminal region of RelA/p65, which contains a Lys-310 residue (Fig. 3b) and inhibits histone deacetylase recruitment on their complex to turn off the NF-κB signaling pathway. Although we did not confirm that acetylation of residue RelA/p65 is critical for interaction with TIP60 in this study, it seems that p300-mediated RelA/p65 acetylation could be modulated by TIP60 through a protein interaction.

Previous studies reveal that the activation of NF-κB, a hallmark of inflammatory responses that is frequently detected in tumors, might constitute a link between inflammation and cancer (58–60). The inflammatory process triggers hepatocyte NF-κB through up-regulation of TNF-α in adjacent endothelial and inflammatory cells (42, 61). We also confirmed that the expression of Ac-Lys-310 RelA/p65 was up-regulated in hepatocarcinoma tissues in contrast to normal liver tissues (Fig. 7b). Furthermore, TIP60 expression was increased in TNM stage II of a moderately differentiated hepatocarcinoma (Table 1). Our findings here showed that TIP60 expression might be correlated with RelA/p65 in the early stage of hepatocarcinoma generation. We also suggest the possibility that sustainable high expression of TIP60 delays the “turn-off” signal of the NF-κB

### Table 1

| Tissue types                  | n  | Positive rate of TIP60 expression |
|-------------------------------|----|----------------------------------|
| Non-neoplastic liver          | 9  | 22.2 (2/9)                       |
| Hepatocarcinoma               | 38 | 34.2 (13/38)                     |
| Cholangiocarcinoma            | 2  | 0 (0/2)                          |
| Metastatic carcinoma          | 10 | 10 (1/10)                        |
| Total tissues                 | 59 |                                  |

**Clinical-pathologic factors**

| Histological differentiation | Positive rate of TIP60 expression |
|------------------------------|----------------------------------|
| High and moderate            | 25 (9/25)                        |
| Poor                         | 5 (1/5)                          |
| TNM stage                    |                                  |
| I                            | 15.4 (2/13)                      |
| II                           | 61.5 (8/13)                      |
| III                          | 15.4 (2/13)                      |
| IV                           | 7.7 (1/13)                       |
TIP60 Enhances Transcriptional Activity of RelA/p65

pathway by maintaining acetylated K310-RelA/p65 through a protein interaction that correlated with activated NF-κB signaling in hepatocarcinomas (Fig. 7).

The identification of TIP60 as a coactivator of NF-κB RelA/p65 suggests a novel mechanism for the enhanced transcriptional activity of activated RelA/p65. Unlike other coactivators that recognize the acetylation code of transcription factors, the occupancies of TIP60 on the subset of NF-κB targets gene promoters were preceded by independent of transcription factor binding. Moreover, a knockdown of TIP60 significantly reduced acetylated histones H3/H4 and recruitment of RelA/p65 on the promoter regions. Therefore, in TNF-α-induced NF-κB activation, phosphorylation of RelA/p65 facilitates the recruitment of p300/CBP to acetylate RelA/p65, and TIP60 opens the chromatin structure to allow promotion of NF-κB recognition sites. Acetylated RelA/p65 positioned on the promoter recruits other cofactors to execute transcription initiation involving basal transcription factor recruitment (Fig. 7, c–e). Our study will contribute to a better understanding of the regulation of transcriptional activation of NF-κB in a view of chromatin remodeling, which is mediated by a protein–protein interaction and a protein–DNA interaction. Furthermore, regulation of the interaction between TIP60 and NF-κB might be a potential target for the systemic inhibition of NF-κB pathway and for therapeutic approaches of NF-κB-mediated carcinogenesis.

Acknowledgments—We thank Prof. Cheol O. Joe (Department of Biological Science of KAIST, South Korea) for providing the expression plasmids of GST-fused RelA/p65 full-length, N320, and C321. We also thank Prof. Sung-Hee Baek (Seoul National University, South Korea) for providing the expression plasmid of FLAG-TIP60 HAT mutant. We thank Prof. Jin Won Cho (Department of Biology, Yonsei University, South Korea) for providing the RelA/p65 Δc1/MEF cell line and Prof. Sangmyung Rhee (School of Biological Sciences, Chung-Ang University, South Korea) for RelA/p65+/− MEF cell line.

REFERENCES

1. Bonizzi, G., and Karin, M. (2004) The two NF-κB activation pathways and their role in innate and adaptive immunity. *Trends Immunol.* 25, 280–288
2. Ghosh, S., May, M. J., and Kopp, E. B. (1998) NF-κB and Rel proteins. Evolutionarily conserved mediators of immune responses. *Annu. Rev. Immunol.* 16, 225–260
3. Hayden, M. S., and Ghosh, S. (2004) Signaling to NF-κB. *Genes Dev.* 18, 2195–2224
4. Chen, F. E., and Ghosh, G. (1999) Regulation of DNA binding by Rel/NF-κB transcription factors. Structural views. *Oncogene* 18, 6645–6652
5. Thanos, D., and Maniatis, T. (1995) NF-κB. A lesson in family values. *Cell* 80, 529–532
6. Pahl, H. L. (1999) Activators and target genes of Rel/NF-κB transcription factors. *Oncogene* 18, 6853–6866
7. Ghosh, S., and Karin, M. (2002) Missing pieces in the NF-κB puzzle. *Cell* 109, S81–S96
8. Chen, Z. J., Parent, L., and Maniatis, T. (1996) Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. *Cell* 84, 853–862
9. Palombella, V. J., Rando, O. J., Goldberg, A. L., and Maniatis, T. (1994) The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. *Cell* 78, 773–785
10. Rice, N. R., and Ernst, M. K. (1993) In vivo control of NF-κB activation by IκBα. *EMBO J.* 12, 4685–4695
11. Beg, A. A., Finco, T. S., Nantermet, P. V., and Baldwin, A. S., Jr. (1993) Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκBα. A mechanism for NF-κB activation. *Mol. Cell. Biol.* 13, 3301–3310
12. Henkel, T., Machleidt, T., Alkalay, I., Krönke, M., Ben-Neriah, Y., and Baeuerle, P. A. (1993) Rapid proteolysis of IκBα is necessary for activation of transcription factor NF-κB. *Nature* 365, 182–185
13. Adams, C. M., and Workman, J. L. (1995) Binding of disparate transcriptional activators to nucleosomal DNA is inherently cooperative. *Mol. Cell. Biol.* 15, 1405–1421
14. Taylor, I. C., Workman, J. L., Schuetz, T. J., and Kingston, R. E. (1991) Facilitated binding of GAL4 and heat shock factor to nucleosomal templates. Differential function of DNA binding domains. *Genes Dev.* 5, 1285–1298
15. Adkins, M. W., and Tyler, J. K. (2006) Transcriptional activators are dispensable for transcription in the absence of Sp1-mediated chromatin reassembly of promoter regions. *Mol. Cell* 21, 405–416
16. Utley, R. T., Côté, J., Owen-Hughes, T., and Workman, J. L. (1997) SWI/SNF stimulates the formation of disparate activator-nucleosome complexes but is partially redundant with cooperative binding. *J. Biol. Chem.* 272, 12642–12649
17. Guccione, E., Martinato, F., Finocchiario, G., Luzi, L., Tizzoni, L., Dall’Olio, V., Zardo, G., Nervi, C., Bernard, L., and Amati, B. (2006) Myc binding site recognition in the human genome is determined by chromatin context. *Nat. Cell Biol.* 8, 764–770
18. Gerritsen, M. E., Williams, A. J., Neish, A. S., Moore, S., Shi, Y., and Collins, T. (1997) CREB-binding protein/p300 are transcriptional coactivators of p65. *Proc. Natl. Acad. Sci. USA* 94, 2927–2932
19. Glass, C. K., Rose, D. W., and Rosenfeld, M. G. (1997) Nuclear receptor coactivators. *Carr. Opin. Cell Biol.* 9, 222–232
20. Sheppard, K. A., Rose, D. W., Haque, Z. K., Kurokawa, R., Mcinerney, E., Westin, S., Thanos, D., Rosenfeld, M. G., Glass, C. K., and Collins, T. (1999) Transcriptional activation by NF-κB requires multiple coactivators. *Mol. Cell. Biol.* 19, 6367–6378
21. Torchia, J., Glass, C., and Rosenfeld, M. G. (1998) Co-activators and corepressors in the integration of transcriptional responses. *Curr. Opin. Cell Biol.* 10, 373–383
22. Buerki, C., Rothgiesser, K. M., Valovka, T., Owen, H. R., Rehrahner, H., Fey, M., Lane, W. S., and Hottinger, M. O. (2008) Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA/p65. *Nucleic Acids Res.* 36, 1665–1680
23. Kiernan, R., Blès, V., Ng, R. W., Coudard, M. P., El Messaoudi, S., Sardet, C., Jin, D. Y., Emiliani, S., and Benkirane, M. (2003) Post-activation turnoff of NF-κB-dependent transcription is regulated by acetylation of p65. *J. Biol. Chem.* 278, 2758–2766
24. Rothgiesser, K. M., Fey, M., and Hottinger, M. O. (2010) Acetylation of p65 at lysine 314 is important for late NF-κB-dependent gene expression. *BMC Genomics* 11, 22
25. Kamine, J., Elangovan, B., Subramanian, T., Coleman, D., and Chinnadurai, G. (1996) Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator. *Virology* 216, 357–366
26. Yang, X. J. (2004) The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. *Nucleic Acids Res.* 32, 959–976
27. Sapountzi, V., Logan, I. R., and Robson, C. N. (2006) Cellular functions of Tip60. *Int. J. Biochem. Cell Biol.* 38, 1496–1509
28. Cao, X., and Südhof, T. C. (2001) A transcriptionally active complex of APP with F65 and histone acetyltransferase Tip60. *Science* 293, 115–120
29. Brady, M. E., Ozanne, D. M., Gaughan, L., Waite, I., Cook, S., Neal, D. E., and Robson, C. N. (1999) Tip60 is a nuclear hormone receptor coactivator. *J. Biol. Chem.* 274, 17599–17604
30. Halkidou, K., Gnanapragasam, V. J., Mehta, P. B., Logan, I. R., Brady, M. E., Cook, S., Leung, H. Y., Neal, D. E., and Robson, C. N. (2003) Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. *Oncogene* 22, 2466–2477
31. Kim, J. W., Jang, S. M., Kim, C. H., An, J. H., Kang, E. J., and Choi, K. H. (2010) Tip60 regulates myoblast differentiation by enhancing the transcriptional activity of MyoD via their physical interactions. *FEBS J.* 278,
TIP60 Enhances Transcriptional Activity of RelA/p65

4394–4404

32. Sykies, S. M., Mellert, H. S., Holbert, M. A., Li, K., Marmoerstein, R., Lane, W. S., and McMahon, S. B. (2006) Acetylation of the p53 DNA binding domain regulates apoptosis induction. Mol. Cell 24, 841–851

33. Tang, Y., Luo, J., Zhang, W., and Gu, W. (2006) Tip60-dependent acetylation of p53 modulates the decision between cell cycle arrest and apoptosis. Mol. Cell 24, 827–839

34. Xiao, H., Chung, J., Song, P. I., Jeong, M. H., An, J. H., Lee, S. Y., Jang, S. M., Song, K. H., Armstrong, C. A., and Choi, K. H. (2008) TIP60 represses transcriptional activity of p73β via an MDM2-bridged ternary complex. J. Biol. Chem. 283, 20077–20086

35. Park, J., Lee, J. H., La, M., Jung, M. J., Chae, G. W., Kim, S. B., Tak, H., Jung, Y., Byun, B., Ahn, J. K., and Joe, C. O. (2007) Inhibition of NF-κB acetylation and its transcriptional activity by Daxx. J. Mol. Biol. 368, 388–397

36. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method. Methods 25, 402–408

37. Tang, Y., Luo, J., Armstrong, C. A., and Choi, K. H. (2008) TIP60 represses transcriptional activity of p73β via an MDM2-bridged ternary complex. J. Biol. Chem. 283, 20077–20086

38. Tai, D. I., Tsai, S. L., Chang, Y. H., Huang, S. N., Chen, T. C., Chang, K. S., Hsueh, W. S., and McMahon, S. B. (2006) Acetylation of the p53 DNA binding domain to activation of the tumor suppressor Tip60. Mol. Cell 21, 1376–1382

39. Chen, L. F., Mu, Y., and Greene, W. C. (2002) Acetylation of RelA at lysine 9. Nature 416, 103–107

40. Frank, S. R., Parisi, T., Taubert, S., Fernandez, P., Fuchs, M., Chan, H. M., Livingston, D. M., and Amati, B. (2003) MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep. 4, 575–580

41. Chen, L. F., Mu, Y., and Greene, W. C. (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO J. 21, 6539–6548

42. Kirsch, C., and Rosen, C. A. (1993) NF-κB substrate-specific regulation of the interleukin-8 promoter. Mol. Cell. Biol. 13, 6137–6146

43. Matsuoka, T., Fujikawa, K., Nishio, Y., Mukaida, N., Matsuhashi, K., Kishimoto, T., and Akira, S. (1993) Transcription factors NF-IL6 and NF-κB synergistically activate transcription of the inflammatory cytokines interleukin 6 and interleukin 8. Proc. Natl. Acad. Sci. U.S.A. 90, 10193–10197

44. Erl, W., Hansson, G. K., de Martin, R., Draude, G., Weber, K. S., and Weber, C. (1999) Nuclear factor-κB regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. Circ. Res. 84, 668–677

45. Steblk, C., de Martin, R., Kumabashiri, I., Schmid, J. A., Binder, B. R., and Lipp, J. (1998) Nuclear factor (NF)-κB-regulated X chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis. J. Exp. Med. 188, 211–216

46. Wang, Y., Chan, S., and Tsang, B. K. (2002) Involvement of inhibitory nuclear factor-κB (NF-κB)-independent NF-κB activation in the gonadotrophic regulation of X-linked inhibitor of apoptosis expression during ovarian follicular development in vitro. Endocrinology 143, 2732–2740

47. Huang, B., Yang, X. D., Zhou, M. M., Ozato, K., and Chen, L. F. (2009) Brd4 coactivates transcriptional activation of NF-κB via specific binding to acetylated RelA. Mol. Cell. Biol. 29, 1375–1387

48. Baek, S. H., Ohgi, K. A., Rose, D. W., Koo, E. H., Glass, C. K., and Rosenfeld, M. G. (2002) Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-κB and β-amyloid precursor protein. Cell 110, 55–67

49. Jones, D. O., Cowell, I. G., and Singh, P. B. (2000) Mammalian chromodomain proteins. Their role in genome organization and expression. Bioessays 22, 124–137

50. Nielsen, P. R., Nieltspsch, D., Mott, H. R., Callaghan, J., Bannister, A., Kouzarides, T., Murzin, A. G., Murzina, N. V., and Lau, E. D. (2002) Structure of the HP1 chromodomain bound to histone H3 methylated at lysine 9. Nature 416, 103–107

51. Sun, Y., Jiang, X., Xu, Y., Ayrapetov, M. K., Moreau, L. A., Whetstine, J. R., and Price, B. D. (2009) Histone H3 methylation links DNA damage detection to activation of the tumor suppressor Tip60. Nat. Cell Biol. 11, 1376–1382

52. Frank, S. R., Parisi, T., Taubert, S., Fernandez, P., Fuchs, M., Chan, H. M., Livingston, D. M., and Amati, B. (2003) MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep. 4, 575–580

53. Chen, L. F., Mu, Y., and Greene, W. C. (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO J. 21, 6539–6548

54. Gyrd-Hansen, M., Darding, M., Miasma, M., Santoro, M. M., Zender, L., Xue, W., Tenev, T., da Fonseca, P. C., Zvelebit, M., Bujnicki, J. M., Lowe, S., Silke, J., and Meier, K. P. (2008) IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-κB as well as cell survival and oncogenesis. Nat. Cell Biol. 10, 1309–1317

55. Karin, M. (2009) NF-κB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect. Biol. 1, a000141

56. Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., and Ben-Neriah, Y. (2004) NF-κB functions as a tumor promoter in inflammation-associated cancer. Nature 431, 461–466

57. Frau, M., Biasi, F., Feo, F., and Pascale, R. M. (2010) Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol. Aspects Med. 31, 179–193